Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

2025-523232-39-00 Protocol MS743701_0001 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 2 sites · Protocol MS743701_0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 58
Countries 1
Sites 2

Advanced Solid Tumors

Key facts

Sponsor
Merck Healthcare KGaA
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2026-03-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
27.1 PT 10061873 Non-small cell lung cancer 100000004864
20.0 PT 10075566 Triple negative breast cancer 100000004864
20.0 PT 10073364 Ductal adenocarcinoma of pancreas 100000004864
21.1 PT 10017758 Gastric cancer 100000004864
20.0 PT 10061328 Ovarian epithelial cancer 100000004864
26.1 PT 10060121 Squamous cell carcinoma of head and neck 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Healthcare KGaA

Sponsor organisation
Merck Healthcare KGaA
Address
Frankfurter Strasse 250
City
Darmstadt
Postcode
64293
Country
Germany

Scientific contact point

Organisation
Merck Healthcare KGaA
Contact name
Global Regulatory Affairs

Public contact point

Organisation
Merck Healthcare KGaA
Contact name
Global Regulatory Affairs

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruitment pending 14 2
Rest of world
Canada, Japan, United States
44

Investigational sites

Spain

2 sites · Authorised, recruitment pending
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-17 Spain Acceptable
2026-02-27
2026-03-03
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-13 Spain Acceptable
2026-02-27
2026-03-13